REGIONAL ADMINISTRATION OF LYMPHOKINE-ACTIVATED KILLER-CELLS CAN BE SUPERIOR TO INTRAVENOUS APPLICATION

Citation
U. Keilholz et al., REGIONAL ADMINISTRATION OF LYMPHOKINE-ACTIVATED KILLER-CELLS CAN BE SUPERIOR TO INTRAVENOUS APPLICATION, Cancer, 69(8), 1992, pp. 2172-2175
Citations number
13
Language
INGLESE
art.tipo
Article
Journal title
CancerACNP
ISSN journal
0008-543X
Volume
69
Issue
8
Year of publication
1992
Pages
2172 - 2175
Database
ISI
SICI code
0008-543X(1992)69:8<2172:RAOLKC>2.0.ZU;2-F
Abstract
A patient with liver metastases of human lymphocyte antigen (HLA) clas s II-negative malignant melanoma was treated with several cycles of ad optive immunotherapy with interleukin-2 and lymphokine-activated kille r (LAK) cells. The authors evaluated the efficacy of regional transfer of LAK cells versus systemic intravenous administration. Initially, t he patient was treated according to a regional treatment protocol, con sisting of perfusion of the spleen with interleukin-2 and transfer of LAK cells into the portal vein; a partial remission was observed. Beca use of technical problems, interleukin-2 and LAK cells were administer ed intravenously in a second treatment cycle. This systemic treatment course resulted only in a minor mixed response of the hepatic metastas es. A third treatment course was administered with the use of intraven ous interleukin-2 infusion and arterial perfusion of the liver with LA K cells. The patient had separate hepatic arteries to both lobes of th e liver as an anatomic variation. Because most of the tumor mass was p resent in the right lobe of the liver, a third of the LAK cells were i njected into the right hepatic artery and the remaining cells were adm inistered intravenously. The lesions in the right lobe of the liver re gressed, but disease progression occurred in the left lobe. A fourth t reatment cycle, consisting of intravenous infusion of interleukin-2 an d arterial perfusion of both lobes of the liver with LAK cells, result ed in a complete response of all hepatic lesions, which has lasted 18 months to date. Because, in this patient, tumor regression was observe d only in anatomic areas of the liver, which were perfused with LAK ce lls, it is suggested that the regional administration of LAK cells was essential for successful treatment.